Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Director Yadin Rozov Buys 20,000 Shares

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) Director Yadin Rozov acquired 20,000 shares of the firm’s stock in a transaction that occurred on Monday, March 13th. The shares were bought at an average price of $1.96 per share, with a total value of $39,200.00. Following the acquisition, the director now directly owns 36,500 shares in the company, valued at $71,540. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Oramed Pharmaceuticals Stock Up 0.9 %

Shares of Oramed Pharmaceuticals stock opened at $2.23 on Friday. The firm’s 50 day moving average price is $2.60 and its 200-day moving average price is $6.14. Oramed Pharmaceuticals Inc. has a 52-week low of $1.81 and a 52-week high of $13.73. The company has a market cap of $88.71 million, a P/E ratio of -2.37 and a beta of 1.83.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ORMP. Lindbrook Capital LLC purchased a new position in shares of Oramed Pharmaceuticals in the 4th quarter worth approximately $4,612,000. Renaissance Technologies LLC purchased a new position in shares of Oramed Pharmaceuticals in the 2nd quarter worth approximately $1,647,000. JPMorgan Chase & Co. grew its position in shares of Oramed Pharmaceuticals by 1,796.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 336,549 shares of the biotechnology company’s stock worth $1,541,000 after buying an additional 318,801 shares during the last quarter. BlackRock Inc. grew its position in shares of Oramed Pharmaceuticals by 17.4% in the 1st quarter. BlackRock Inc. now owns 1,830,166 shares of the biotechnology company’s stock worth $15,832,000 after buying an additional 271,559 shares during the last quarter. Finally, Bank of Montreal Can purchased a new position in shares of Oramed Pharmaceuticals in the 2nd quarter worth approximately $1,348,000. Hedge funds and other institutional investors own 10.08% of the company’s stock.

Wall Street Analysts Forecast Growth

ORMP has been the subject of several recent research reports. StockNews.com initiated coverage on shares of Oramed Pharmaceuticals in a report on Thursday. They issued a “hold” rating for the company. Canaccord Genuity Group lowered shares of Oramed Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the company from $30.00 to $3.00 in a report on Thursday, January 12th. HC Wainwright lowered shares of Oramed Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday, January 17th. Finally, Cantor Fitzgerald lowered shares of Oramed Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Friday, January 13th.

Oramed Pharmaceuticals Company Profile

(Get Rating)

Oramed Pharmaceuticals, Inc engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.